See the DrugPatentWatch profile for cosentyx

Cosentyx, also known as secukinumab, is a medication used to treat a variety of conditions including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [1]. The recommended dosing intervals for Cosentyx can vary depending on the specific condition being treated and the individual patient's response to treatment.

For the treatment of plaque psoriasis, the recommended dosing interval for Cosentyx is 300 mg administered via subcutaneous injection at weeks 0, 1, 2, 3, and 4, followed by maintenance doses of 300 mg every 4 weeks [1]. However, for some patients, a maintenance dose of 300 mg every 8 weeks may be sufficient [1].

For the treatment of psoriatic arthritis, the recommended dosing interval for Cosentyx is 300 mg administered via subcutaneous injection at weeks 0, 1, 2, 3, and 4, followed by maintenance doses of 300 mg every 4 weeks [1]. In some cases, a maintenance dose of 150 mg every 4 weeks may be considered [1].

For the treatment of ankylosing spondylitis, the recommended dosing interval for Cosentyx is 150 mg administered via subcutaneous injection at weeks 0, 1, 2, 3, and 4, followed by maintenance doses of 150 mg every 4 weeks [1].

It's important to note that the dosing intervals for Cosentyx may be adjusted based on a patient's response to treatment and individual needs [1]. Additionally, it's important to follow the prescribing information provided by the manufacturer and consult with a healthcare provider for personalized dosing recommendations [1].

In summary, the recommended dosing intervals for Cosentyx are as follows:

* Plaque psoriasis: 300 mg every 4 weeks (with some patients potentially able to switch to every 8 weeks)
* Psoriatic arthritis: 300 mg every 4 weeks (with some patients potentially able to switch to 150 mg every 4 weeks)
* Ankylosing spondylitis: 150 mg every 4 weeks

Sources:
[1] <https://www.drugpatentwatch.com/brands/cosentyx-secukinumab>